These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26906299)

  • 1. Use of Glucuronidated Mycophenolic Acid Levels for Therapeutic Monitoring in Pediatric Lupus Nephritis Patients.
    Hui-Yuen JS; Tran T; Taylor J; Truong K; Li X; Bermudez LM; Starr AJ; Eichenfield AH; Imundo LF; Askanase AD
    J Clin Rheumatol; 2016 Mar; 22(2):75-9. PubMed ID: 26906299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis.
    Kittanamongkolchai W; Rukrung C; Supasiri T; Lertjirachai I; Somparn P; Chariyavilaskul P; Avihingsanon Y
    Lupus; 2013 Jun; 22(7):727-32. PubMed ID: 23651860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis.
    Godron-Dubrasquet A; Woillard JB; Decramer S; Fila M; Guigonis V; Tellier S; Morin D; Sordet M; Saint-Marcoux F; Harambat J
    Pediatr Nephrol; 2021 Feb; 36(2):341-347. PubMed ID: 32856157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation on the benefits of mycophenolate mofetil and therapeutic drug monitoring in the treatment of Japanese patients with lupus nephritis.
    Katsuno T; Ozaki T; Ozeki T; Hachiya A; Kim H; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Mizuno M; Ito Y; Maruyama S
    Clin Exp Nephrol; 2018 Dec; 22(6):1341-1350. PubMed ID: 29796823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil.
    Daleboudt GM; Reinders ME; den Hartigh J; Huizinga TW; Rabelink AJ; de Fijter JW; Berger SP
    Lupus; 2013 Feb; 22(2):171-9. PubMed ID: 23257398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study.
    Zhang L; Chen L; Liu X; Huang Z; Zheng Y; Tang K; Jiang X; Chen P
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI180-SI187. PubMed ID: 38730553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring.
    Łuszczyńska P; Pawiński T; Kunicki PK; Durlik M; Augustyniak-Bartosik H; Hurkacz M
    Eur J Clin Pharmacol; 2019 Mar; 75(3):371-379. PubMed ID: 30430214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
    Tönshoff B; David-Neto E; Ettenger R; Filler G; van Gelder T; Goebel J; Kuypers DR; Tsai E; Vinks AA; Weber LT; Zimmerhackl LB
    Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Drug Monitoring of Mycophenolic Acid in Lupus Nephritis: A Review of Current Literature.
    Łuszczyńska P; Pawiński T
    Ther Drug Monit; 2015 Dec; 37(6):711-7. PubMed ID: 26034895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters.
    Sobiak J; Resztak M; Ostalska-Nowicka D; Zachwieja J; Gąsiorowska K; Piechanowska W; Chrzanowska M
    Eur J Pharm Sci; 2015 Sep; 77():189-96. PubMed ID: 26102431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring.
    Zabotti A; Baraldo M; Quartuccio L; Sacco S; De Marchi G; De Vita S
    Clin Rheumatol; 2015 Jan; 34(1):171-4. PubMed ID: 25249327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN).
    Ranganathan D; Abdul-Aziz MH; John GT; McWhinney BC; Fassett RG; Healy H; Kubler P; Lim A; Lipman J; Purvey M; Roberts M; Reyaldeen R; Ungerer J; Roberts JA
    Ther Drug Monit; 2019 Dec; 41(6):703-713. PubMed ID: 31219949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. To TDM or not to TDM in lupus nephritis patients treated with MMF?
    van Gelder T; Berden JH; Berger SP
    Nephrol Dial Transplant; 2015 Apr; 30(4):560-4. PubMed ID: 24811231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related variability of mycophenolate mofetil exposure in stable pediatric liver transplant recipients and influences of donor characteristics.
    Parant F; Rivet C; Boulieu R; Gagnieu MC; Dumortier J; Boillot O; Lachaux A
    Ther Drug Monit; 2009 Dec; 31(6):727-33. PubMed ID: 19881404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.
    Tredger JM; Brown NW; Adams J; Gonde CE; Dhawan A; Rela M; Heaton N
    Liver Transpl; 2004 Apr; 10(4):492-502. PubMed ID: 15048791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Mycophenolate Mofetil for the Treatment of Juvenile-Onset Proliferative Lupus Nephritis.
    Tian SY; Silverman ED; Pullenayegum E; Brown PE; Beyene J; Feldman BM
    Arthritis Care Res (Hoboken); 2017 Dec; 69(12):1887-1894. PubMed ID: 28182833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue.
    Alsmadi MM; Alfarah MQ; Albderat J; Alsalaita G; AlMardini R; Hamadi S; Al-Ghazawi A; Abu-Duhair O; Idkaidek N
    Biopharm Drug Dispos; 2019 Nov; 40(9):325-340. PubMed ID: 31674040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of trough mycophenolic acid levels for the management of lupus nephritis.
    Pourafshar N; Karimi A; Wen X; Sobel E; Pourafshar S; Agrawal N; Segal E; Mohandas R; Segal MS
    Nephrol Dial Transplant; 2019 Jan; 34(1):83-89. PubMed ID: 29548021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis.
    Daudén E; Sánchez-Peinado C; Ruiz-Genao D; García-F-Villalta M; Onate MJ; García-Díez A
    Br J Dermatol; 2004 Jan; 150(1):132-5. PubMed ID: 14746627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.